Structure Encountered

Enterome

Develops microbiome-derived peptide cancer immunotherapies targeting tumor-associated antigens

Enterome's OncoMimics vaccine EO2463 won FDA Orphan Drug status in watch-and-wait indolent lymphoma.

SIGNAL·FDA Orphan Drug Designation·7-yr exclusivity·SCORE 67·02 JUN 2026 · 11:54 UTC

● CAPTURE — IMAGE INCOMINGFRAME 01 / 01

STRUCT. / ENTEROME

/ Paris, France

CAPT. / 02.06.26 11:54:29Z

SIGNAL / 67 / 100

Image relayed by The Biotech Voyager during pass over structure Enterome. Resolution as transmitted.

001Vital Statistics

DATA LOCKED

Designation

Enterome

Coordinates

Paris, France

Stage

Phase2

Type

Therapeutics

Modalities

peptide · vaccine · microbiome

Therapeutic area

Oncology · Hematology

002Signature Detected

EVENT DETECTED

Event type

FDA Orphan Drug Designation

Magnitude

7-yr exclusivity

Lead

U.S. FDA

Participating

Prior Fast Track (Oct 2025)

003Architecture

PLATFORM PROFILE

Target class

Tumor-associated antigens in indolent non-Hodgkin lymphoma, reached indirectly: gut-bacterial peptides that mimic those antigens and awaken cross-reactive effector memory CD8 T cells.

Differentiator

Cancer vaccines usually fight immune tolerance to self-antigens. OncoMimics sidesteps it by using microbial look-alikes the immune system already attacks, redirecting that pre-built T-cell army at the tumor. Off-the-shelf, not personalized.

Lead asset

EO2463 (OncoMimics), Phase 2; Phase 3 planned 2026

Pipeline depth

3 OncoMimics programs: EO2463 (iNHL), EO2401 (GBM/adrenal), EO4010 (CRC)

004Voyager Assessment

MACHINE-GENERATED

Here's a clever trick. Most cancer vaccines fight an uphill battle against tolerance, because tumor antigens look like your own tissue. Enterome's OncoMimics platform uses peptides from gut bacteria that happen to mimic tumor antigens, so it borrows the immune system's existing army of antimicrobial memory T cells and points it at the cancer. EO2463 has Orphan Drug status in indolent non-Hodgkin lymphoma, on top of a Fast Track from October, aimed at watch-and-wait patients who currently get nothing. Enterome is openly shopping for partners. Watch the SIDNEY Phase 2 biomarker readout at EHA and a planned Phase 3.

005Adjacent Structures

FRONTIER MAP

Roche· rituximab in FLBioNTech· cancer vaccinesModerna· mRNA cancer vaccineNykode Therapeutics· off-the-shelf cancer vaccineGenmab· epcoritamab in NHL

— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.